Imavita is proud to announce New Team members with the recent recruitment of Maud Chusseau and Julia Rochotte. Maud Chusseau, MSc, Research Scientist, Maud is graduated from University
All the team of Imavita wishes to all collaborators, colleagues, customers and suppliers and their families, an excellent and happy new year 2019!
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies associated with imaging and image analysis, announces its participation in the collaborative project Pi-R2
IMAVITA S.A.S., société de services et d’innovation dans les modèles précliniques de pathologies humaines associées à l’imagerie et l’analyse d’images, annonce sa participation au projet collaboratif PiR2 /
Imavita released the use of OCT (Optical Coherence Tomography) for in vivo imaging in the following applications: Dermatology Atopic dermatitis / Oxazolone & IL23 models Psoriasis / IMQ
Imavita is proud to announce the acquisition of new Optical Coherence Tomography apparatus to develop Innovating imaging of dermatology models. Since september 2017, Imavita is working on this
Since January 2nd 2017, Imavita laboratories address moved to Canal Biotech 1, 3 rue des Satellites, 31400 Toulouse, France. This address will be the same for headquarters. The
Team is growing! Imavita is proud to announce the recent recruitment of Elisabeth Bonnard and Jeanne Chapel. Dr Elisabeth Bonnard, Neuropharmacologist, PhD, Project Leader, was graduated on 2004
Imavita is proud to announce the acquisition of new Fluorescence Molecular Tomography imaging apparatus for the evaluation of its models. Since october 2016, a Fluorescence Tomography system was
©2013-2025 Imavita S.A.S. All rights reserved. | Legal mentions.